<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://cardiologytalk.com/videoEmbed/51/declare-timi-58-hfref-%7C-acc.19?channelName=_5feba5631406a&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

DECLARE-TIMI 58 HFrEF - ACC.19

Name: DECLARE-TIMI 58 HFrEF - ACC.19
Uploaded: 2020-12-29T01:43:57
Duration: 4 min 22 s
Description: Dr. Peter Block interviews presenter Dr. Eri Toda Kato regarding dapagliflozin on HF and mortality in diabetes based on EF (DECLARE TIMI-58). Visit http://www.acc.org/ACC19 for full meeting coverage.

00:04:22

American College of Cardiology

2 years 13 Views

Share Add to Report 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://cardiologytalk.com/videoEmbed/51/declare-timi-58-hfref-%7C-acc.19?channelName=_5feba5631406a&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://cardiologytalk.com/videoEmbed/51/declare-timi-58-hfref-%7C-acc.19?channelName=_5feba5631406a&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://cardiologytalk.com/videoEmbed/51/declare-timi-58-hfref-%7C-acc.19?channelName=_5feba5631406a&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://cardiologytalk.com/v/51?channelName=_5feba5631406a"><img src="https://cardiologytalk.com/videos/_YPTuniqid_5feba31d38a277.47459724/_YPTuniqid_5feba31d38a277.47459724.jpg?cache=16092783161666223222">DECLARE-TIMI 58 HFrEF | ACC.19</a>

Link (BBCode):

[url=https://cardiologytalk.com/v/51?channelName=_5feba5631406a][img]https://cardiologytalk.com/videos/_YPTuniqid_5feba31d38a277.47459724/_YPTuniqid_5feba31d38a277.47459724.jpg?cache=16092783161666223222[/img]DECLARE-TIMI 58 HFrEF | ACC.19[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Acute Coronary Syndromes

Description:

Dr. Peter Block interviews presenter Dr. Eri Toda Kato regarding dapagliflozin on HF and mortality in diabetes based on EF (DECLARE TIMI-58). Visit http://www.acc.org/ACC19 for full meeting coverage.